Observational Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Apr 6, 2022; 10(10): 3101-3112
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3101
Table 1 Study population
Age of patientsyr
Median63
Mean60.6
Minimum32
Maximum82
Level of education
Primary education21%
Upper secondary education53%
Master/doctoral education26%
Gender
Male56.4%
Female43.6%
Initial stage
Stage II high risk3.9%
Stage III34.7%
Stage IV61.4%
Purpose of treatment
Curative41.6%
Palliative56.4%
Undefined2.0%
Karnofsky performance status
100%5.9%
90%45.5%
80%36.5%
70%6.9%
60%5%
Chemotherapy
FOLFOX37.4%
CapeOX45.5%
Other17.1%
Relevant comorbidities
None55.2%
Diabetes mellitus10.3%
Alcohol abuse3.3%
Cardio-vascular diseases20.1%
Other11.1%
Diabetes-insulin treatment
Yes8.4%
No91.6%
Table 2 Patient’s status at the time of study enrollment
Treatment status
Still going on35.7%
Stopped due to neuropathy30.8%
Stopped due to toxicity16.7%
Finished chemotherapy16.8%
Types of toxicity
Neuropathy30.8%
Hematologic28.2%
Digestive12.4%
Dermatologic3.5%
Mixed25.1%